HOME >> BIOLOGY >> NEWS
Clinical trial data regarding NKTR-061 will be presented at ATS International Conference

San Francisco, Calif. -- Results of a Phase 2a clinical trial evaluating the potential of NKTR-061 (inhaled amikacin) to treat hospital acquired gram-negative bacterial pneumonia will be presented at the American Thoracic Society (ATS) International Conference, May 18 23, 2007, in San Francisco.

WHO: Dr. Michael S. Niederman, MD, Chairman, Department of Medicine, Winthrop-University Hospital, Professor of Medicine; Vice Chairman, Department of Medicine, SUNY at Mineoloa.

Dr. Jean Chastre, Professor of Medicine, University of Paris.

WHAT: Four posters detailing the results of a Phase 2a clinical trial evaluating the pharmacokinetic, serum and tracheal aspirate concentration, safety and antibiotic reduction properties of NKTR-061.

Data will be presented and discussed at this ATS session to show a reduction in the use of IV antibiotics in mechanically ventilated patients during treatment of gram-negative pneumonia with NKTR-061. Further, the data indicate that the administration of NKTR-061 resulted in high tracheal aspirate concentrations and high epithelial lining fluid concentrations of amikacin in gram-negative pneumonia in intubated mechanically ventilated patients. Finally, data will be presented indicating that NKTR-061 achieves safe serum concentrations following multiple dosing in intubated mechanically ventilated patients with gram-negative pneumonia.

WHEN: Monday, May 21st, 2007, 8:15-11:00 am (PT)

WHERE: The American Thoracic Society (ATS) International Conference at the San Francisco Marriott Hotel.

ABOUT NKTR-061:

NKTR-061 (inhaled amikacin) is being tested to evaluate the safety and tolerability of amikacin formulated for inhalation for the adjunctive treatment of gram-negative pneumonia in ventilated patients diagnosed with hospital or ventilator associated pneumonia. This new inhaled antibiotics product candidate leverages N
'"/>

Contact: Tim Warner
twarner@nektar.com
650-283-4915
Nektar Therapeutics
9-May-2007


Page: 1 2

Related biology news :

1. 2007-2008 Genzyme/ACMGF Clinical Genetics Fellowship In Biochemical Genetics award winner announced
2. Scientists honored with Excellence in Clinical Research Award
3. Clinical trial for diabetic macular edema
4. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
5. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
6. American College of Medical Genetics -- 2007 Annual Clinical Genetics Meeting Announcement
7. October MCP: A special issue on Clinical Proteomics
8. Columbia University Medical Center receives major new NIH Clinical Science investment funds
9. Researchers reverse juvenile diabetes in animal model; Clinical trial FDA approved
10. Clinical trial to test stem cell approach for children with brain injury
11. Vaccine trials inject hope into koalas future

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/1/2020)... ... April 01, 2020 , ... ... has named Jean-François Duliere as a European Regulatory Advisor. Effective 1 April 2020, ... compliance and facilities design for biotechnology, oral solid dosage (OSD), and sterile manufacturing. ...
(Date:3/20/2020)... ... 2020 , ... ImStem Biotechnology, Inc. (Farmington CT), a biopharmaceutical ... cells (hES-MSC), through a proprietary method using a trophoblast intermediate stage (hence also ... today announced that the U.S. Food and Drug Administration (FDA) has lifted the ...
(Date:3/13/2020)... ... March 13, 2020 , ... According to ... can cause conjunctivitis and possibly be transmitted by aerosol or direct contact with ... wearers should take special precautions to avoid contracting the coronavirus. Touching the eyes ...
Breaking Biology News(10 mins):
(Date:4/1/2020)... SALT LAKE CITY, and LA JOLLA, Calif. (PRWEB) , ... March ... ... and characterization tools, and La Jolla Institute for Immunology (LJI), announced today that they ... few days allowing CoVIC to move therapeutic candidates to the clinic as early as ...
(Date:3/19/2020)... (PRWEB) , ... March 17, ... ... clinical supply and manufacturing collaboration agreement with pioneering gene circuit company Senti ... therapies for ovarian cancer and other solid tumor indications. The collaboration will ...
(Date:3/10/2020)... , ... March 10, 2020 , ... Ortho Clinical Diagnostics, ... innovative laboratory solutions, announced its ORTHOTM Sera, ID-MTS, a suite of extended antigen in ... is cleared to run on ORTHO VISION® and ORTHO VISION® Max in the United ...
(Date:3/4/2020)... ... March 04, 2020 , ... This month, Cognosante will make its ... company will showcase both expanded and emerging offerings that align with the HIMSS annual ... designed to be comprehensive, timely, and engaging. From Interoperability and HIE ...
Breaking Biology Technology:
Cached News: